Flucostat (Fluconazole) capsules

Flucostat (Fluconazole) capsules

To favorites
Flucostat (Fluconazole) capsules representative of the class of triazole antifungal agents, is a powerful selective inhibitor of the synthesis of sterols in the fungal cell, has a high specificity for fungal enzymes
Active substance:Fluconazole
Pharmacological group:Antifungal
Country of origin:Russia
In stock
In stock
In stock
We deliver goods to almost any country. Each parcel is assigned a track number
You can pay by Paypal or any card Visa or Mastercard
Discount system
Cumulative discounts and Bonus program for our clients
Original goods
We offer our customers only original products

Flucostat (Fluconazole) capsules

English product name

Release form
caps. 50 mg: 7 pcs.
caps. 150 mg: 1 pc.

Description Fluconazole:

Capsules opaque, white color, №0; The capsule contents are white or almost white powder.

1 cap.
fluconazole 150 mg
Auxiliary substances:
Silica colloidal (aerosyl),
magnesium stearate,
sodium lauryl sulfate,

Capsule shell composition: gelatin, methylparahydroxybenzoate, propyl parahydroxybenzoate, titanium dioxide (E171), acetic acid.

ATC codes
J02AC01 Fluconazole

Clinical-pharmacological groups / Group affiliation
Antifungal preparation

Active substance

Pharmacotherapy group
Antifungal agent

Storage Conditions Fluconazole
The drug Fluconazole should be stored in a place inaccessible to children at a temperature of fifteen to twenty-five degrees

Best before date
The shelf life is two years.

Testimony Flucostat:

  • cryptococcosis, including cryptococcal meningitis and other localizations of this infection (including lungs, skin), 
  • both in patients with a normal immune response, and in patients with various forms of immunosuppression (including AIDS
  • patients, for organ transplantation); the drug can be used to prevent cryptococcal infection in AIDS patients;
  • generalized candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidiasis infection
  • (including abdominal, endocardium, eye,
  • respiratory and urinary tract infections). Treatment may be carried out in patients with malignant neoplasms, patients with
  • intensive care units, patients receiving cytotoxic or immunosuppressive agents, as well as in the presence of other factors
  • predisposing to the development of candidiasis;
  • Candidiasis of mucous membranes, including mouth and throat (including atrophic candidiasis of the oral cavity associated
  • with dental prostheses), esophagus, non-invasive bronchopulmonary infections, candiuria; Prevention of the recurrence of
  • oropharyngeal candidiasis in AIDS patients;
  • genital candidiasis: treatment of vaginal candidiasis (acute and chronic recurrent), prophylactic use to reduce the
  • frequency of recurrence of vaginal candidiasis (three or more episodes per year); Candiose balanite;
  • Prevention of fungal infections in patients with malignant neoplasms that are predisposed to such infections as a result of
  • cytotoxic chemotherapy or radiation therapy;
  • Skin mycosis, including foot mycosis, body, groin area, edema, onychomycosis and candidiasis of the skin;
  • deep endemic mycosis, including coccidioidomycosis, paracocydia idomycosis, sporotrichosis and histoplasmosis in patients
  • with normal immunity.

Method of use, course and dosage Flucostat:

The drug is taken inside.

Adults with cryptococcal meningitis and cryptococcal infections of another location are given 400 mg on the first day, and then continue treatment in a dose of 200-400 mg 1 time/day. The duration of treatment for cryptococcal infections depends on the clinical efficacy confirmed by the mycological study; For cryptococcal meningitis, therapy usually lasts at least 6-8 weeks.

In order to prevent the recurrence of cryptococcal meningitis in AIDS patients, after completing the full course of primary treatment, fluconazole therapy at a dose of 200 mg per day can be continued for a long time.For candidemia, disseminated candidiasis and other invasive candidiasis infections, the dose is 400 mg on average in the first day and then 200 mg per day. If not sufficiently effective, the dose can be increased to 400 mg/day. The duration of therapy depends on clinical effectiveness.

For oropharyngeal candidiasis, the drug is prescribed on average 50-100 mg once a day; The duration of therapy is 7-14 days. If necessary, treatment may be longer in patients with a marked reduction in immunity.
In the case of oral candidiasis atrophic associated with dentures, the preparation is administered at an average dose of 50 mg once/day for fourteen days in combination with local antiseptic agents for the treatment of the prosthesis.

Pharmacological effect Flucostat:

Antifungal drug. Fluconazole is a class of triazole antifungals, a potent selective inhibitor of sterol synthesis in the fungal cell.
Active against opportunistic mycosis pathogens, including those caused by Candida spp., Cryptococcus neoformans, Microsporum spp., Trichophyton spp. Fluconazole activity is also shown in models of endemic mycosis, including infections caused by Blastomyces dermatitidis, Coccidioides immitis and Histoplasma capsulatum.

Use in children
Contraindication: Children under 3 years of age.

  • Nosology Flucostat (ICD codes)
  • B20..
  • A disease caused by the human immunodeficiency virus [HIV] in the form of infectious and parasitic diseases
  • B20.4
  • Disease caused by HIV with manifestations of candidiasis
  • B35.0
  • Mikoz beards and heads
  • B35.1
  • Nail mycosis
  • B35.2
  • Mikoz brushes
  • B35.3
  • Mycosis stop
  • B35.4
  • Torso mycosis
  • B35.6
  • Epidermofitia
  • B36.0
  • Multicolored fox
  • B37.0
  • Candidiasis stomatitis
  • B37.1
  • Pulmonary candidiasis
  • B37.2
  • Skin and nail candidiasis
  • B37.3
  • Candidiasis vulva and vagina
  • B37.4
  • Candidiasis of other urogenital localizations
  • B37.6
  • Candida endocarditis
  • B37.7
  • Candidiasis sepsis
  • B37.8
  • Candidiasis of other localizations (including candidiasis enteritis)
  • B38..
  • Coccidioidomycosis
  • B39..
  • Histoplasmosis
  • B41..
  • Paracocydiidomycosis
  • B42..
  • Sporotrichosus
  • B45..
  • Cryptococcosis
  • H19.2
  • Keratitis and keratoconjunctivitis in other infectious and parasitic diseases classified in other headings
  • Z29.8
  • Other specific preventive measures
Active substance
Pharmacological group
Country of origin
Expiration Date (in months)
No reviews yet — your comment may be first.
All reviews 0
general rating